UNSPSC 51241134: Pegaptanib sodium

This classification denotes an angiogenesis inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3HP012Q0FH. European Medicines Agency schedules Pegaptanib sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21226. Pegaptanib sodium generally arises in the molecular formula C15H28N3O6(C2H4O)N(C2H4O)N.28NA. The term 'pegaptanib sodium' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule pegaptanib sodium under HS 39072021 and SITC 57419.

Pegaptanib sodium bears US NLM identifiers UMLS ID C0967532 and NCI Concept Code C95230. SMILES: As of Q4 2014, PEGAPTANIB SODIUM remains US FDA's Preferred Term for this commodity.

UNSPSC 51241134 Pegaptanib sodium is a Commodity code covering pharmaceutical products supplied through state and local government cooperative purchasing arrangements. Recent solicitations show this code tags multisource generic pharmaceuticals and over-the-counter products distributed across participating public facilities, with suppliers required to maintain current Good Manufacturing Practices certification, Drug Supply Chain Security Act compliance, and contractual relationships with authorized pharmaceutical wholesalers. State and local issuing bodies using this code include multistate cooperative purchasing alliances and their member agencies—departments of health, corrections, human services, and public safety facilities that source drugs through established vendor networks and wholesaler chargeback systems. The work centers on manufacturer-level supply agreements that establish fixed or variable pricing (flat price, net price, or WAC-minus formats), product data submission with National Drug Codes and packaging specifications, and ongoing compliance reporting; suppliers also bear administrative fees (typically 3 percent) and performance penalty exposure for reporting delays or onboarding failures.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued the most recent representative solicitation—RFP S1070000015802 for generic multisource pharmaceuticals and OTC products, posted January 20, 2026, with a response deadline of March 26, 2026. The MMCAP procurement spans Minnesota and Oregon member jurisdictions and evaluates proposals on price competitiveness (75 percent weight), fixed pricing stability (10 percent), EDI capability (5 percent), administrative-fee compliance (5 percent), and data format compliance (5 percent). Awarded vendors must maintain commercial general liability coverage of $5 million per occurrence and professional liability of $2 million, with contract terms of two years for new vendors and alignment to existing expiration dates (through June 30, 2028) for incumbent responders. MMCAP reserves discretion for sole, dual, or multi-awards based on therapeutic need and member-specific requirements, with products required to be available in the marketplace by May 15, 2026, and resulting agreements effective July 1, 2026.